Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70


Mdm2's dilemma: to degrade or to translate p53?

Hamard PJ, Manfredi JJ.

Cancer Cell. 2012 Jan 17;21(1):3-5. doi: 10.1016/j.ccr.2011.12.018.


The p53 mRNA-Mdm2 interaction controls Mdm2 nuclear trafficking and is required for p53 activation following DNA damage.

Gajjar M, Candeias MM, Malbert-Colas L, Mazars A, Fujita J, Olivares-Illana V, Fåhraeus R.

Cancer Cell. 2012 Jan 17;21(1):25-35. doi: 10.1016/j.ccr.2011.11.016.


A genetic approach to mapping the p53 binding site in the MDM2 protein.

Freedman DA, Epstein CB, Roth JC, Levine AJ.

Mol Med. 1997 Apr;3(4):248-59.


Concepts in MDM2 Signaling: Allosteric Regulation and Feedback Loops.

Ponnuswamy A, Hupp T, Fåhraeus R.

Genes Cancer. 2012 Mar;3(3-4):291-7. doi: 10.1177/1947601912454140.


Regulation of p53 and MDM2 activity by MTBP.

Brady M, Vlatkovic N, Boyd MT.

Mol Cell Biol. 2005 Jan;25(2):545-53.


Hdmx stabilizes Mdm2 and p53.

Stad R, Ramos YF, Little N, Grivell S, Attema J, van Der Eb AJ, Jochemsen AG.

J Biol Chem. 2000 Sep 8;275(36):28039-44.


P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2.

Tao W, Levine AJ.

Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6937-41.


The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53.

Pomerantz J, Schreiber-Agus N, Liégeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C, DePinho RA.

Cell. 1998 Mar 20;92(6):713-23.


MDM2 increases drug resistance in cancer cells by inducing EMT independent of p53.

Sun W, Tang L.

Curr Med Chem. 2016 Sep 26. [Epub ahead of print]


Dual role of p300 in the regulation of p53 stability.

Kawai H, Nie L, Wiederschain D, Yuan ZM.

J Biol Chem. 2001 Dec 7;276(49):45928-32. Epub 2001 Oct 8.


ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage.

Maya R, Balass M, Kim ST, Shkedy D, Leal JF, Shifman O, Moas M, Buschmann T, Ronai Z, Shiloh Y, Kastan MB, Katzir E, Oren M.

Genes Dev. 2001 May 1;15(9):1067-77.


Evidence that the human cytomegalovirus IE2-86 protein binds mdm2 and facilitates mdm2 degradation.

Zhang Z, Evers DL, McCarville JF, Dantonel JC, Huong SM, Huang ES.

J Virol. 2006 Apr;80(8):3833-43.


Targeting MDM2-p53 interaction for cancer therapy: are we there yet?

Nag S, Zhang X, Srivenugopal KS, Wang MH, Wang W, Zhang R.

Curr Med Chem. 2014;21(5):553-74. Review.


P53 mRNA controls p53 activity by managing Mdm2 functions.

Candeias MM, Malbert-Colas L, Powell DJ, Daskalogianni C, Maslon MM, Naski N, Bourougaa K, Calvo F, Fåhraeus R.

Nat Cell Biol. 2008 Sep;10(9):1098-105. doi: 10.1038/ncb1770.


Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation.

Goldberg Z, Vogt Sionov R, Berger M, Zwang Y, Perets R, Van Etten RA, Oren M, Taya Y, Haupt Y.

EMBO J. 2002 Jul 15;21(14):3715-27.


RING domain-mediated interaction is a requirement for MDM2's E3 ligase activity.

Kawai H, Lopez-Pajares V, Kim MM, Wiederschain D, Yuan ZM.

Cancer Res. 2007 Jul 1;67(13):6026-30.


Defects in transcription coupled repair interfere with expression of p90(MDM2) in response to ultraviolet light.

Michalowski J, Seavey SE, Mendrysa SM, Perry ME.

Oncogene. 2001 Sep 13;20(41):5856-64.


PKB/Akt activation inhibits p53-mediated HIF1A degradation that is independent of MDM2.

Choy MK, Movassagh M, Bennett MR, Foo RS.

J Cell Physiol. 2010 Mar;222(3):635-9. doi: 10.1002/jcp.21980.


ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage.

Chen L, Gilkes DM, Pan Y, Lane WS, Chen J.

EMBO J. 2005 Oct 5;24(19):3411-22. Epub 2005 Sep 15.

Items per page

Supplemental Content

Write to the Help Desk